Berenberg upgrades Mowi stock rating to Buy on 2026 salmon price outlook

Berenberg upgraded Mowi ASA from Hold to Buy and raised its price target to NOK 260 (from NOK 215), citing expected industry tailwinds in 2026 including significantly higher salmon prices and lower farming costs. The bank highlights Mowi's improved fish-health performance in Norway, favorable conditions in Chile and the acquisition of Nova Sea (adding ~52,000 tpa), and forecasts roughly EUR 1.6 EBIT/kg which could more than double 2026 EBIT versus 2025; Berenberg's 2026 EBIT is ~8% above consensus. The upgrade and raised forecasts increase analyst visibility on Mowi’s 2026 earnings leverage and potential upside to the share price.

Analysis

Market Structure: Mowi (MOWI.OL) is a clear beneficiary from Berenberg’s upgrade—an incremental ~52k tpa from Nova Sea is a mid-single-digit boost to output and shifts near-term share toward the largest, integrated players while pressuring smaller regional farms. Conversely, short-term losers include smaller salmon producers (e.g., SALM.OL, LSG.OL) and feed-only suppliers if Mowi captures downstream margin; the CME data-center outage hurts execution-sensitive liquidity providers, HFTs and options desks and temporarily elevates booking risk for listed derivatives venues.

Risk Assessment: Tail risks include a major fish-health event in 12–24 months, unexpected feed-cost inflation (soy/maize up >15%), or integration failure at Nova Sea that erodes projected EUR1.6/kg EBIT; for CME, regulatory fines or client litigation could depress EBITDA by low double-digits over 12 months. Immediate impact (days) is volatility and execution frictions; short-term (weeks–months) depends on Q4 trading volumes and initial Nova Sea integration signals; long-term (2026) hinges on realized salmon prices versus Berenberg’s bullish scenario.

Trade Implications: Direct play: establish a 2–3% long position in MOWI.OL targeting NOK260 in 9–15 months, scale to 5% on pullback >5% or after confirmation of 1H26 price recovery. Pair trade: long MOWI.OL (2%) vs short SALM.OL (equal notional) to express consolidation-driven market-share gains; options: buy a 12–18 month call spread on MOWI (buy ATM, sell 30% OTM) to cap cost, and buy 6–9 month 10–15% OTM puts on CME (CME) sized to 0.5–1% portfolio risk to hedge exchange execution/regulatory shock.

Contrarian Angles: Consensus may understate integration and biosecurity risk—if salmon prices fall <5% from current forecasts or feed costs rise >10%, upside evaporates and multiple compression could exceed 20% within 12 months. The CME outage reaction is likely overdone for long-term franchise value; favor exchange peers with redundant infra (NYSE:ICE, LSE:LSE) if regulatory scrutiny forces higher capex and widens moat economics for better-capitalized operators.

Key Decisions for Investors

• Establish a 2–3% long position in MOWI.OL (Oslo) with a 9–15 month horizon; increase to 5% if MOWI confirms >5% production uplift or consensus 2026 EBIT revisions exceed +10%.
• Implement a relative-value pair: long MOWI.OL 2% vs short SALM.OL equal notional to capture expected market-share gains and margin convergence over 6–12 months.
• Buy a cost‑limited options structure on MOWI: 12–18 month call spread (buy ATM call, sell 30% OTM call) sized to 1–2% portfolio risk to participate in 2026 upside while capping premium outlay.
• Hedge exchange execution/regulatory tail risk by buying 6–9 month puts on CME (CME) 10–15% OTM sized to 0.5–1% portfolio risk; alternatively add/selectively long ICE (NYSE:ICE) or LSE (LSE:LSE) on a 6–12 month horizon if regulatory capex becomes a structural moat.